Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

Charlotte E Coles, Clare L Griffin, Anna M Kirby, Jenny Titley, Rajiv K Agrawal, Abdulla Alhasso, Indrani S Bhattacharya, Adrian M Brunt, Laura Ciurlionis, Charlie Chan, Ellen M Donovan, Marie A Emson, Adrian N Harnett, Joanne S Haviland, Penelope Hopwood, Monica L Jefford, Ronald Kaggwa, Elinor J Sawyer, Isabel Syndikus, Yat M Tsang, Duncan A Wheatley, Maggie Wilcox, John R Yarnold, Judith M Bliss, IMPORT Trialists, Wail Al Sarakbi, Sarah Barber, Gillian Barnett, Peter Bliss, John Dewar, David Eaton, Stephen Ebbs, Ian Ellis, Philip Evans, Emma Harris, Hayley James, Cliona Kirwan, Julie Kirk, Helen Mayles, Anne McIntyre, Judith Mills, Andrew Poynter, Elena Provenzano, Christine Rawlings, Mark Sculpher, Georges Sumo, Mark Sydenham, Andrew Tutt, Nicola Twyman, Karen Venables, Anna Winship, John Winstanley, Gordon Wishart, Alastair Thompson, Charlotte E Coles, Clare L Griffin, Anna M Kirby, Jenny Titley, Rajiv K Agrawal, Abdulla Alhasso, Indrani S Bhattacharya, Adrian M Brunt, Laura Ciurlionis, Charlie Chan, Ellen M Donovan, Marie A Emson, Adrian N Harnett, Joanne S Haviland, Penelope Hopwood, Monica L Jefford, Ronald Kaggwa, Elinor J Sawyer, Isabel Syndikus, Yat M Tsang, Duncan A Wheatley, Maggie Wilcox, John R Yarnold, Judith M Bliss, IMPORT Trialists, Wail Al Sarakbi, Sarah Barber, Gillian Barnett, Peter Bliss, John Dewar, David Eaton, Stephen Ebbs, Ian Ellis, Philip Evans, Emma Harris, Hayley James, Cliona Kirwan, Julie Kirk, Helen Mayles, Anne McIntyre, Judith Mills, Andrew Poynter, Elena Provenzano, Christine Rawlings, Mark Sculpher, Georges Sumo, Mark Sydenham, Andrew Tutt, Nicola Twyman, Karen Venables, Anna Winship, John Winstanley, Gordon Wishart, Alastair Thompson

Abstract

Background: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy restricted to the vicinity of the original tumour in women at lower than average risk of local relapse will improve the balance of beneficial versus adverse effects compared with whole-breast radiotherapy.

Methods: IMPORT LOW is a multicentre, randomised, controlled, phase 3, non-inferiority trial done in 30 radiotherapy centres in the UK. Women aged 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal adenocarcinoma of grade 1-3, with a tumour size of 3 cm or less (pT1-2), none to three positive axillary nodes (pN0-1), and minimum microscopic margins of non-cancerous tissue of 2 mm or more, were recruited. Patients were randomly assigned (1:1:1) to receive 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-dose group), or 40 Gy to the partial breast only (partial-breast group) in 15 daily treatment fractions. Computer-generated random permuted blocks (mixed sizes of six and nine) were used to assign patients to groups, stratifying patients by radiotherapy treatment centre. Patients and clinicians were not masked to treatment allocation. Field-in-field intensity-modulated radiotherapy was delivered using standard tangential beams that were simply reduced in length for the partial-breast group. The primary endpoint was ipsilateral local relapse (80% power to exclude a 2·5% increase [non-inferiority margin] at 5 years for each experimental group; non-inferiority was shown if the upper limit of the two-sided 95% CI for the local relapse hazard ratio [HR] was less than 2·03), analysed by intention to treat. Safety analyses were done in all patients for whom data was available (ie, a modified intention-to-treat population). This study is registered in the ISRCTN registry, number ISRCTN12852634.

Findings: Between May 3, 2007, and Oct 5, 2010, 2018 women were recruited. Two women withdrew consent for use of their data in the analysis. 674 patients were analysed in the whole-breast radiotherapy (control) group, 673 in the reduced-dose group, and 669 in the partial-breast group. Median follow-up was 72·2 months (IQR 61·7-83·2), and 5-year estimates of local relapse cumulative incidence were 1·1% (95% CI 0·5-2·3) of patients in the control group, 0·2% (0·02-1·2) in the reduced-dose group, and 0·5% (0·2-1·4) in the partial-breast group. Estimated 5-year absolute differences in local relapse compared with the control group were -0·73% (-0·99 to 0·22) for the reduced-dose and -0·38% (-0·84 to 0·90) for the partial-breast groups. Non-inferiority can be claimed for both reduced-dose and partial-breast radiotherapy, and was confirmed by the test against the critical HR being more than 2·03 (p=0·003 for the reduced-dose group and p=0·016 for the partial-breast group, compared with the whole-breast radiotherapy group). Photographic, patient, and clinical assessments recorded similar adverse effects after reduced-dose or partial-breast radiotherapy, including two patient domains achieving statistically significantly lower adverse effects (change in breast appearance [p=0·007 for partial-breast] and breast harder or firmer [p=0·002 for reduced-dose and p<0·0001 for partial-breast]) compared with whole-breast radiotherapy.

Interpretation: We showed non-inferiority of partial-breast and reduced-dose radiotherapy compared with the standard whole-breast radiotherapy in terms of local relapse in a cohort of patients with early breast cancer, and equivalent or fewer late normal-tissue adverse effects were seen. This simple radiotherapy technique is implementable in radiotherapy centres worldwide.

Funding: Cancer Research UK.

Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Radiotherapy technique for partial-breast group Red shows the partial-breast planning target volume and blue shows the radiotherapy field arrangements shaped with multileaf collimators. See appendix p 9 for further details.
Figure 2
Figure 2
Trial profile *Two patients withdrew consent for any of their data to be used in the analysis.
Figure 3
Figure 3
Cumulative hazard of local relapse by treatment group HR=hazard ratio.

References

    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707–1716.
    1. Breast radiotherapy after breast-conserving surgery The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists. CMAJ. 1998;158(suppl 3):S35–S42.
    1. Sedlmayer F, Sautter-Bihl ML, Budach W. DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol. 2013;189:825–833.
    1. Belkacemi Y, Kaidar-Person O, Poortmans P. Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey. Ann Oncol. 2015;26:529–535.
    1. Dundas KL, Pogson EM, Batumalai V. Australian survey on current practices for breast radiotherapy. J Med Imaging Radiat Oncol. 2015;59:736–742.
    1. Smith BD, Arthur DW, Buchholz TA. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO) Int J Radiat Oncol Biol Phys. 2009;74:987–1001.
    1. Polgár C, Major T, Fodor J. Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother Oncol. 2010;94:274–279.
    1. Polgár C, Van Limbergen E, Pötter R. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009) Radiother Oncol. 2010;94:264–273.
    1. Wilkinson JB, Beitsch PD, Shah C. Evaluation of current consensus statement recommendations for accelerated partial breast irradiation: a pooled analysis of William Beaumont Hospital and American Society of Breast Surgeon MammoSite Registry Trial Data. Int J Radiat Oncol Biol Phys. 2013;85:1179–1185.
    1. Shah C, Vicini F, Wazer DE, Arthur D, Patel RR. The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy. 2013;12:267–277.
    1. Mannino M, Yarnold JR. Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld? Radiother Oncol. 2009;90:14–22.
    1. Salvadori B, Marubini E, Miceli R. Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery. Br J Surg. 1999;86:84–87.
    1. Coles CE, Wilson CB, Cumming J. Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. Eur J Surg Oncol. 2009;35:578–582.
    1. Harris EJ, Donovan EM, Yarnold JR, Coles CE, Evans PM, IMPORT Trial Management Group Characterization of target volume changes during breast radiotherapy using implanted fiducial markers and portal imaging. Int J Radiat Oncol Biol Phys. 2009;73:958–966.
    1. Coles CE, Donovan E, Haviland J, Yarnold J. Intensity-modulated radiotherapy for the treatment of breast cancer. Clin Oncol. 2013;25:215.
    1. Théberge V, Whelan T, Shaitelman SF, Vicini FA. Altered fractionation: rationale and justification for whole and partial breast hypofractionated radiotherapy. Semin Radiat Oncol. 2011;21:55–65.
    1. Marta GN, Macedo CR, Carvalho Hde A, Hanna SA, da Silva JL, Riera R. Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials. Radiother Oncol. 2015;114:42–49.
    1. Strnad V, Ott OJ, Hildebrandt G, on behalf of the Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387:229–238.
    1. Haviland JS, Owen JR, Dewar JA, on behalf of the START Trialists' Group The UK Standardisation of Breast Radiotherapy (START) randomised trials of radiotherapy hypofractionation for treatment of early breast cancer; 10-year follow-up results (CRUK/96/001) Lancet Oncol. 2013;14:1086–1094.
    1. Schaverien MV, Stallard S, Dodwell D, Doughty JC. Use of boost radiotherapy in oncoplastic breast-conserving surgery—a systematic review. Eur J Surg Oncol. 2013;39:1179–1185.
    1. Yarnold J, Ashton A, Bliss J. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005;75:9–17.
    1. Haviland JS, Ashton A, Broad B. Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer. Clin Oncol. 2008;20:497–501.
    1. Veronesi U, Orecchia R, Maisonneuve P. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269–1277.
    1. Livi L, Meattini I, Marrazzo L. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51:451–463.
    1. Olivotto IA, Whelan TJ, Parpia S. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 2013;31:4038–4045.
    1. Haviland JS, Hopwood P, Mills J, Sydenham M, Bliss JM, Yarnold JR, on behalf of the START Trialists' Group Do patient-reported outcome measures agree with clinical and photographic assessments of normal tissue effects after breast radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) trials in early breast cancer. Clin Oncol. 2016;28:345–353.
    1. Donovan EM, James H, Bonora M, Yarnold JR, Evans PM. Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer. Med Phys. 2012;39:5814–5824.
    1. Kirby AM, Evans PM, Donovan EM, Convery HM, Haviland JS, Yarnold JR. Prone versus supine positioning for whole and partial-breast radiotherapy: a comparison of non-target tissue dosimetry. Radiother Oncol. 2010;96:178–184.
    1. Gentilini O, Botteri E, Leonardi MC. Ipsilateral axillary recurrence after breast conservative surgery: the protective effect of whole breast radiotherapy. Radiother Oncol. 2017;122:37–44.
    1. Mukesh MB, Barnett GC, Wilkinson JS. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol. 2013;31:4488–4495.
    1. Vaidya JS, Wenz F, Bulsara M, on behalf of the TARGIT trialists' group Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603–613.
    1. Bloomfield DJ, on behalf of the Core Group facilitated by The Royal College of Radiologists Development of postoperative radiotherapy for breast cancer: UK consensus statements—a model of patient, clinical and commissioner engagement? Clin Oncol. 2017 published online July 4.
    1. Giuliano AE, Ballman K, McCall L. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (alliance) ACOSOG Z0011 Randomized Trial. Ann Surg. 2016;264:413–420.
    1. Galimberti V, Cole BF, Zurrida S, for the International Breast Cancer Study Group Trial 23–01 investigators Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305.
    1. Whelan TJ, Olivotto IA, Parulekar WR, for the MA.20 Study Investigators Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307–316.
    1. Poortmans PM, Collette S, Kirkove C, for the EORTC Radiation Oncology and Breast Cancer Groups Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317–327.
    1. Hickey BE, Lehman M, Francis DP, See AM. Partial breast irradiation for early breast cancer. Cochrane Database Syst Rev. 2016;7 CD007077.

Source: PubMed

3
Předplatit